A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 557 participants.

Also called NCT01952145

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 557 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01952145
  • EudraCT 2012-004413-14
Main results
  • Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial JAMA, 2016-03-01 DOI, PubMed 26934259 PubMed links an erratum for this paper. Erratum: PMID 27187314; Erratum: PMID 27187315
Other papers using this trial's data
  • EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2019-02 DOI, PubMed 30383495
  • Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA Advances in therapy, 2017-04 DOI, PubMed 28281218, PMC5435780 PubMed links an erratum for this paper. Erratum: PMID 28523624 In the PMC Open Access subset under CC BY-NC.
  • Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA Journal of medical economics, 2017-07 DOI, PubMed 28294641
  • Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial Diabetes, obesity & metabolism, 2018-01 DOI, PubMed 28643425, PMC5763397 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Greece, Hungary, Mexico, Russia, Slovakia, South Africa, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01952145. Randomized; no masking; primary purpose treatment. Start 2013-09-20 (actual); primary completion 2014-11-04 (actual). Results posted on 2017-01-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
Acronym
DUAL™ V
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec/liraglutide
Intervention (Drug)
insulin glargine
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01952145
Content hash
e197812521c6a662871fb682ae88001b0748bb4c95cf70ff5c1cf9a6ce75abb9